Log in

NASDAQ:APTOAptose Biosciences Stock Price, Forecast & News

$7.07
+0.09 (+1.29 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.77
Now: $7.07
$7.22
50-Day Range
$6.81
MA: $7.66
$8.43
52-Week Range
$1.81
Now: $7.07
$9.25
Volume547,609 shs
Average Volume596,409 shs
Market Capitalization$631.14 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More
Aptose Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APTO
CUSIPN/A
Phone858-926-2730

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.23 per share

Profitability

Net Income$-26,280,000.00

Miscellaneous

Employees31
Market Cap$631.14 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.

Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

How has Aptose Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APTO shares have increased by 21.1% and is now trading at $7.07. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aptose Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptose Biosciences.

When is Aptose Biosciences' next earnings date?

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aptose Biosciences.

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) issued its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.05. View Aptose Biosciences' earnings history.

What price target have analysts set for APTO?

4 Wall Street analysts have issued twelve-month target prices for Aptose Biosciences' stock. Their forecasts range from $9.00 to $16.00. On average, they anticipate Aptose Biosciences' share price to reach $12.00 in the next year. This suggests a possible upside of 69.7% from the stock's current price. View analysts' price targets for Aptose Biosciences.

Has Aptose Biosciences been receiving favorable news coverage?

Media stories about APTO stock have trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptose Biosciences earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAptose Biosciences.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 991,600 shares, an increase of 59.6% from the April 30th total of 621,300 shares. Based on an average daily trading volume, of 995,400 shares, the days-to-cover ratio is presently 1.0 days. Approximately 1.4% of the company's stock are sold short. View Aptose Biosciences' Current Options Chain.

Who are some of Aptose Biosciences' key competitors?

What other stocks do shareholders of Aptose Biosciences own?

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the following people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Corriente Advisors LLC (3.83%), Pictet Asset Management Ltd. (2.08%), Precept Management LLC (1.02%), Orbimed Advisors LLC (0.74%), P.A.W. Capital Corp (0.79%) and Morgan Stanley (0.53%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow and William G Rice. View institutional ownership trends for Aptose Biosciences.

Which major investors are selling Aptose Biosciences stock?

APTO stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sanders Morris Harris LLC, P.A.W. Capital Corp, Morgan Stanley, Morgan Stanley, and Two Sigma Advisers LP. View insider buying and selling activity for Aptose Biosciences.

Which major investors are buying Aptose Biosciences stock?

APTO stock was acquired by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, Pictet Asset Management Ltd., Precept Management LLC, Atom Investors LP, BNP Paribas Arbitrage SA, Advisor Group Holdings Inc., Patriot Financial Group Insurance Agency LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow, and William G Rice. View insider buying and selling activity for Aptose Biosciences.

How do I buy shares of Aptose Biosciences?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $7.07.

How big of a company is Aptose Biosciences?

Aptose Biosciences has a market capitalization of $631.14 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 31 workers across the globe.

What is Aptose Biosciences' official website?

The official website for Aptose Biosciences is www.aptose.com.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 12770 HIGH BLUFF DRIVE SUITE 120, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-926-2730 or via email at [email protected]

This page was last updated on 6/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.